Literature DB >> 32351233

Medical cannabis as an alternative therapeutics for Parkinsons' disease: Systematic review.

Anastasia Bougea1, Christos Koros2, Athina-Maria Simitsi2, Chrysa Chrysovitsanou2, Athanasios Leonardos2, Leonidas Stefanis2.   

Abstract

OBJECTIVES: 1) to evaluate the efficacy of medical cannabinoids (MC) by appraising the quality of evidence from clinical studies 2) to explore the factors hampering the MC use in clinical practice of Parkinson's disease (PD).
METHODS: We performed a systematic review through various databases. The quality of 14 studies was assessed by Cochrane risk bias (5 randomized controlled trials- RCT) and Newcastle-Ottawa scale (9 uncontrolled studies).
RESULTS: The positive effects on motor (5 studies) and non-motor symptoms (4 studies) described in uncontrolled studies have not been confirmed by the few and small RCTs. Only one RCT found a reduction of levodopa-induced dyskinesias, another a reduction in anxiety and tremor amplitude in an anxiogenic situation, while the remaining three without effect on motor/non-motor symptoms. Physical and psychological symptoms are among the most common side effects.
CONCLUSIONS: There is insufficient evidence to reform international legislation regarding cannabis use in PD practice.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Legislation; Levodopa-induced dyskinesias; Medical cannabinoids (MC); Parkinson's disease (PD); Randomized controlled trials (RCT); Side effects

Year:  2020        PMID: 32351233     DOI: 10.1016/j.ctcp.2020.101154

Source DB:  PubMed          Journal:  Complement Ther Clin Pract        ISSN: 1744-3881            Impact factor:   2.446


  4 in total

Review 1.  Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review.

Authors:  P Oikonomou; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2022-07-20       Impact factor: 3.850

2.  Cannabis and its derivatives for the use of motor symptoms in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Susan J Thanabalasingam; Brandan Ranjith; Robyn Jackson; Don Thiwanka Wijeratne
Journal:  Ther Adv Neurol Disord       Date:  2021-05-25       Impact factor: 6.570

Review 3.  Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective.

Authors:  Santosh V Suryavanshi; Igor Kovalchuk; Olga Kovalchuk
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

4.  Effects of Cannabidiol on Parkinson's Disease in a Transgenic Mouse Model by Gut-Brain Metabolic Analysis.

Authors:  Jinchuan Zhao; Xin Gao; Liangyou Zhao; Yiqing Wang; Jingbo Zhang; Shumin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-22       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.